Date:4/12/2012

s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 as filed with the SEC on February 9, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subseque
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Perceptive Informatics Completes Over 500 System Integrations as the Biopharma Industry Continues to Adopt Seamless eClinical Solutions
2. Perceptive Informatics® DataLabs® EDC Solution Ranks Highest in Overall Satisfaction
3. Perceptive Informatics® Global Survey Results Indicate Wide Use of Industry-Standard Medical Imaging Metrics to Meet Study Milestones
4. Perceptive Informatics Brings More Efficiency to Clinical Development Process With SaaS-Based CTMS Solution
5. Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management
6. Perceptive Informatics Integrates Medical Imaging Tracking with RTSM Technologies for Streamlined Workflow, Improved Data Quality
7. Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite
8. Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials
9. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
10. Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimers Treatments
11. Perceptive Informatics Improves Clinical Trial Management With Enhanced TrialWorks(R) Solution